Information Provided By:
Fly News Breaks for March 1, 2016
NVAX
Mar 1, 2016 | 07:30 EDT
FBR Capital analyst Vernon Bernardino says yesterday's post-earnings pullback in shares of Novavax is unwarranted. The company's spending "is high, but not out of control," Bernardino tells investors in a research note. The momentum in Novavax's RSV vaccine program is strong, the analyst contends. He views the stock as compelling at current levels and reiterates an Overweight rating on the name with a $17 price target.
News For NVAX From the Last 2 Days
There are no results for your query NVAX